McKesson Raises FY26 EPS Guidance, Announces Q1 Results and Dividend Increase

McKesson Corporation reports Q1 fiscal 2026 results and raises full-year adjusted EPS guidance. The company will host an earnings conference call on August 6 at 4:30 PM ET. McKesson recently increased its quarterly dividend by 15% to $0.82 per share. The corporation completed the acquisition of Core Ventures in June 2025, solidifying its position in the healthcare sector. McKesson boasts a market capitalization of $87.28 billion and significant institutional ownership.

McKesson Corporation (NYSE: MCK) has announced its first quarter (Q1) fiscal 2026 results, reporting a significant increase in revenues and adjusted earnings per diluted share (EPS). The company also raised its full-year adjusted EPS guidance for fiscal 2026. The earnings report comes ahead of a scheduled conference call on August 6 at 4:30 PM ET, where investors and analysts can expect to hear more details from the company's leadership.

Key highlights from the Q1 fiscal 2026 results include:

- Revenues: McKesson reported consolidated revenues of $97.8 billion, an increase of 23% compared to the same period last year. The growth was primarily driven by the U.S. Pharmaceutical segment, which saw a 25% increase in revenues due to higher prescription volumes and the distribution of oncology and specialty products.
- Adjusted EPS: Adjusted EPS for the quarter was $8.26, a 5% increase from the previous year. This growth was supported by strong operational performance across the business, partially offset by a higher tax rate and pre-tax gains from McKesson Ventures’ equity investments.
- Dividend Increase: The company's board of directors approved a 15% increase to the quarterly dividend, raising it to $0.82 per share. This marks the ninth consecutive year of dividend increases.
- Acquisitions: McKesson completed the acquisition of an 80% controlling interest in PRISM Vision Holdings, LLC, and a 70% controlling interest in Core Ventures. These acquisitions further expand the company's capabilities in Oncology and Specialty solutions.
- Outlook: McKesson raised its fiscal 2026 adjusted EPS guidance to a range of $37.10 to $37.90, from the previous range of $36.90 to $37.70. The updated guidance includes a 12% to 15% growth compared to the prior year, excluding net gains associated with McKesson Ventures' equity investments, which indicates a 14% to 17% growth.

The company's strong performance in Q1 fiscal 2026 is expected to continue, with the anticipated sale of its retail and distribution businesses in Norway to NorgesGruppen. This transaction is subject to customary closing conditions, including regulatory approvals.

McKesson will host its Investor Day on September 23, 2025, featuring presentations by the company's leadership team and a live Q&A session with CEO Brian Tyler and CFO Britt Vitalone.

For the most up-to-date information and detailed financial statements, investors can refer to McKesson's Investor Relations website.

References:
[1] https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-corporation-reports-fiscal-2026-first-quarter-results/